Clinical studies for AB Science's all-purpose anti-inflammatory drug grind to a halt as company flags potential risk of heart disease

When AB Science claimed a breakout win in Alzheimer’s disease for masitinib, its all-purpose tyrosine kinase inhibitor, in late December, CEO Alain Moussy pointed Endpoints News to safety data across thousands of patients as a key strength of the program — which has seen its share of setbacks and regulatory scorn over the years.